Three years sustained complete remission achieved in a primary refractory ALK-positive anaplastic T large cell lymphoma treated with crizotinib

被引：10

作者：

Valeria Mahuad, Carolina ^{[1
]}

Vicente Reparaz, Maria de los Angeles ^{[1
]}

Zerga, Marta E. ^{[1
]}

Florencia Aizpurua, Maria ^{[1
]}

Casali, Claudia ^{[1
]}

Garate, Gonzalo ^{[1
]}

机构：

[1] Hosp Aleman, Dept Internal Med, Serv Hematol, Pueyrredon 1640, RA-1118 Buenos Aires, DF, Argentina

来源：

RARE TUMORS | 2016年 / 8卷 / 02期

关键词：

Lymphoma; large-cell; anaplastic; anaplastic lymphoma kinase; crizotinib;

D O I：

10.4081/rt.2016.6266

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The prognosis of the primary refractory anaplastic lymphoma kinase (ALK+) anaplastic T large cell lymphoma is ominous. The identification of molecular targets with potential to drive oncogenesis remains a cornerstone for the designing of new selective cancer therapies. Crizotinib is a selective ATP-competitive inhibitor for ALK, approved for its use in lung cancer with rearrangements on ALK gene. The reported cases describe the use of crizotinib as a bridging strategy prior to allotransplantation; there are no reported prolonged survivals under monotherapy with Crizotinib. We report a case of a primary refractory ALK+ anaplastic large-cell lymphoma that sustains complete response after 3 years of crizotinib monotherapy.

引用

页码：88 / 89

页数：2

共 10 条

[1] Anaplastic large cell lymphoma, ALK-positive [J].

Ferreri, Andres J. M. ;

Govi, Silvia ;

Pileri, Stefano A. ;

Savage, Kerry J. .

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2012, 83 (02) :293-302

[2] Brentuximab Vedotin and Crizotinib in Anaplastic Large-Cell Lymphoma [J].

Foyil, Kelley V. ;

Bartlett, Nancy L. .

CANCER JOURNAL, 2012, 18 (05) :450-456

[3] Crizotinib in Anaplastic Large-Cell Lymphoma [J].

Gambacorti-Passerini, Carlo ;

Messa, Cristina ;

Pogliani, Enrico M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (08) :775-776

[4]

Le Gouill S MN, 2004, J CLIN ONCOL, V26, P2264

[5]

Mosse Y, 2012, J CLIN ONCOLOGY, V30

[6] Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study [J].

Mosse, Yael P. ;

Lim, Megan S. ;

Voss, Stephan D. ;

Wilner, Keith ;

Ruffner, Katherine ;

Laliberte, Julie ;

Rolland, Delphine ;

Balis, Frank M. ;

Maris, John M. ;

Weigel, Brenda J. ;

Ingle, Ashish M. ;

Ahern, Charlotte ;

Adamson, Peter C. ;

Blaney, Susan M. .

LANCET ONCOLOGY, 2013, 14 (06) :472-480

[7] ALK-driven tumors and targeted therapy: focus on crizotinib [J].

Murga-Zamalloa, Carlos ;

Lim, Megan S. .

PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2014, 7 :87-94

[8] Use of targeted therapy for refractory ALK-positive anaplastic large cell lymphoma as a bridging strategy prior to allogeneic transplantation [J].

Ordemann, R. ;

Stoehlmacher, J. ;

Beuthien-Baumann, B. ;

Platzek, I. ;

van den Hoff, J. ;

Kroschinsky, F. ;

Middeke, J. M. ;

Platzbecker, U. ;

Zietz, C. ;

Bornhaeuser, M. ;

Ehninger, G. .

ANNALS OF HEMATOLOGY, 2013, 92 (01) :125-127

[9] Crizotinib in Advanced, Chemoresistant Anaplastic Lymphoma Kinase-Positive Lymphoma Patients [J].

Passerini, Carlo Gambacorti ;

Farina, Francesca ;

Stasia, Alessandra ;

Redaelli, Sara ;

Ceccon, Monica ;

Mologni, Luca ;

Messa, Cristina ;

Guerra, Luca ;

Giudici, Giovanni ;

Sala, Elena ;

Mussolin, Lara ;

Deeren, Dries ;

King, Michael H. ;

Steurer, Michael ;

Ordemann, Rainer ;

Cohen, Amos M. ;

Grube, Matthias ;

Bernard, Lea ;

Chiriano, Gianpaolo ;

Antolini, Laura ;

Piazza, Rocco .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2014, 106 (02)

[10] Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma [J].

Zdzalik, Daria ;

Dymek, Barbara ;

Grygielewicz, Paulina ;

Gunerka, Pawel ;

Bujak, Anna ;

Lamparska-Przybysz, Monika ;

Wieczorek, Maciej ;

Dzwonek, Karolina .

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2014, 140 (04) :589-598

← 1 →